-- ZYUS Life Sciences (ZYUS.V) 周二晚间宣布，其全资子公司 ZYUS Life Sciences Inc. 持有的专利已获得美国专利商标局 (USPTO) 的授权（美国专利号：12,616,704），专利名称为“用于疼痛管理的大麻酚制剂”。 该公司表示，该专利基于国际专利申请号 PCT/CA2021/050430，涵盖了一种新型的非致幻性疼痛管理方法。新获授权的专利涉及该公司的第二个候选药物，进一步拓展了其新型专有非阿片类疗法的产品线，并支持正在进行的针对神经性疼痛（包括周围神经病变，例如糖尿病和癌症相关神经病变）的临床研究。 该专利为CBC（无论是作为单一疗法还是作为其主要药物产品——毛霉素软胶囊）提供额外的知识产权保护，并可能赋予其监管独占权，但最终需经美国食品药品监督管理局（FDA）在上市许可时做出监管决定。 “这项美国专利的颁发进一步印证了我们致力于推进差异化新型非阿片类镇痛药物产品组合的承诺，”ZYUS首席执行官Brent Zettl表示，“我们将继续专注于开发创新治疗方案，以满足慢性疼痛和神经性疼痛领域尚未得到满足的重大需求。” 该公司股票在多伦多证券交易所创业板（TSX Venture Exchange）的最新交易价格为0.45美元，与前一日持平。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL